Ta. Bonasera et al., PRECLINICAL EVALUATION OF FLUORINE-18-LABELED ANDROGEN RECEPTOR LIGANDS IN BABOONS, The Journal of nuclear medicine, 37(6), 1996, pp. 1009-1015
A noninvasive method for detecting and quantifying androgen receptors
(AR) in metastatic prostate cancer may be helpful in choosing the meth
od of treatment and in better understanding the pathophysiology of thi
s disease. Nine previously synthesized fluorinated androgens exhibited
high affinity binding to AR acid showed AR-mediated uptake in the ven
tral and dorsal prostate of the rat. Further evaluation of these agent
s for PET imaging is needed since sex hormone binding globulin (SHBG),
a glycoprotein which binds androgens with high affinity, is absent in
rat blood but is present at high levels in the blood of primates. We
chose to study three of the nine fluoro-androgens by PET in the baboon
. Methods: In this study, 16 beta-[F-18]fluoro-5 alpha-dihydrotestoste
rone (I), 16 beta-[F-18]fluoromibolerone (II) and 20-[F-18]fluoromibol
erone (III) were synthesized and studied in both a young and old male
baboon using PET. Blood samples were withdrawn in three of the 10 stud
ies and analyzed for total radioactivity and percent unmetabolized rad
ioligand. Tissue radioactivity was evaluated semiquantitatively, using
prostate absolute, standard and target to nontarget uptake values. Re
sults: Prostate uptake was observed with all three F-18-androgens. At
60 min postinjection, compound I gave the highest prostate to soft tis
sue ratios in both baboons and prostate uptake was shown to be AR-medi
ated by blocking uptake through the coadministration of testosterone.
Compound I gave the highest level of unmetabolized radioligand present
in blood up to 45 min postinjection, and gave a 37-fold greater prost
ate-to-bone ratio at 2 hr postinjection in baboons compared to rats. T
he favorable behavior of this compound in the baboon may be related to
its high affinity for SHBG. Conclusion: All three compounds can be us
ed to determine AR-positive tissue in primates, Compound I was selecte
d for the evaluation of AR in men with prostate cancer using PET.